BEAM-201 is under clinical development by Beam Therapeutics and currently in Phase II for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase II drugs for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BEAM-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BEAM-201 overview

BEAM-201 is under development for the treatment of relapsed/refractory pediatric and adult T-cell acute lymphoblastic leukemia and acute myelocytic leukemia (acute myeloblastic leukemia). The therapeutic candidate consists of allogeneic CAR-T cells modified with base editor which comprises of a guide RNA bound to a modified CRISPR protein and a base editing enzyme, such as a deaminase. It is being developed based on the base editing technology platform based on Lentivirus vector. The drug candidate acts by targeting cells expressing T cell antigen CD7. It is administered through intravenous route.

Beam Therapeutics overview

Beam Therapeutics is a biotechnology company that develops precision genetic medicines for serious diseases. The company develops drugs by using base editing technology which includes the REPAIR system for A-to-I (adenosine to inosine) and the RESCUE system for C-to-U (cytosine to uracil) for ribonucleic acid editing. It is developing BEAM-101 and ESCAPE to treat sickle cell disease and beta-thalassemia; BEAM-201, a multiplex base edited anti-CD7 CAR-T cell investigational therapy for T-cell acute lymphoblastic leukemia and acute myeloid leukemia; BEAM-301 targets glycogen storage disease 1a; BEAM-302 is a liver-targeting lipid nanoparticle formulation for alpha-1 antitrypsin deficiency. Beam Therapeutics is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of BEAM-201’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.